With capital drying up and market tailwinds gone, the biotech industry — including Recursion — needs to make tactical decisions.

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations. Elsewhere, Recursion is laying off 20% of its workforce and Gilead halted several ...

Animal control officers captured a 15-foot python that reportedly terrorized people in a Garland neighborhood.

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and extend cash runway to Q4 2027. Read more here.

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

Recursion Pharmaceuticals plans to slash one-fifth of its workforce as it looks to streamline its operations. The clinical-stage biopharmaceutical company said Tuesday it will reduce its workforce ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Recursion Pharmaceuticals will lay off roughly 20% of its workforce, affecting some 160 employees, in a bid to extend its cash runway. In an SEC filing on Tuesday, the Utah-based biotech announced ...

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy ...

The first beta release of Python 3.14 is now available. This article presents a rundown of the most significant new features in the next version of Python and what they mean for Python developers.